Cohance Lifesciences

** Shares of India's Cohance Lifesciences COHA.NS fall 2.1% to 447 rupees

** The drugmaker says the U.S. FDA inspected its formulation plant in Telangana's Shamshabad from August 27 to September 4

** Adds that inspection concluded with issuance of Form FDA 483 containing four observations

** Stock rated "sell" on average by 8 analysts; median PT is 440 rupees - LSEG-compiled data

** Stock down 15.4%, YTD

(Reporting by Payel Das in Bengaluru)

(([email protected]))

Cohance Lifesciences announced proposed investments totalling $18 million to advance its antibody-drug conjugate strategy, comprising $13 million in NJ Bio and $5 million in Aruka Bio. The NJ Bio investment was expected to raise Cohance’s common-equity ownership from 56% to 67.3%, while Aruka was to become a direct subsidiary by the end of September, subject to definitive agreements, approvals and customary closing conditions. Aruka, a Princeton-based private biotechnology company, had a preclinical lead programme, and the proposed ownership structure assigned 65% direct ownership to Cohance, 25% to NJ Bio and 10% to Dr Naresh Jain before performance-linked dilution. The transactions were to be funded through internal accruals and followed Cohance’s original NJ Bio investment in December 2024. FY26 consolidated revenue was about ₹2,270 crore, with ADC and oligonucleotide activities representing roughly 15% of the business mix.

Powered by Tijori

Cohance Lifesciences approved proposed investments of about $18 million in two US ADC businesses: $13 million to increase its stake in NJ Bio from 56% to 67.3%, and $5 million for about 65% of Aruka Bio on a non-diluted basis. The transactions were to be funded from internal accruals and were expected to close by the end of September, subject to definitive agreements, regulatory approvals and customary conditions. Dr Naresh Jain was to remain NJ Bio's chief executive while taking the same role at Aruka Bio, whose lead programme was at the preclinical stage. NJ Bio reported turnover of $23.5 million in 2025, while Aruka had no revenue in 2023-25. Cohance reported FY26 consolidated revenue of about ₹2,270 crore, with ADC and oligonucleotide activities accounting for roughly 15% of its current mix.

Powered by Tijori

Sept 3 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• INVESTMENT OF USD 18 MILLION IN NJ BIO AND ARUKA BIO

• TO BUY 244,587 NJ BIO SHARES AT $53 PER SHARE FOR $13 MILLION

Source text: ID:nBSEGxWmZ

Further company coverage: COHA.NS

(([email protected];;))

** Shares of Cohance Lifesciences COHA.NS rise 2.1% to 438.9 rupees

** Co expects improvement in Q2 and a return to year-on-year growth in H2, supported by secured orders and scheduled deliveries

** Drugmaker posts Q1 consolidated net loss of 241.2 million rupees ($2.54 million) versus 488.8 million rupees profit a year ago; revenue falls 23%

** Co says lower CDMO contribution, order phasing to H2 and negative operating leverage hurt earnings

** Over 3.4 mln shares traded, 5.1x the 30-day avg

** Stock rated "Hold" on avg; median PT 452.5 rupees - data compiled by LSEG

** Stock down 16.9% YTD

($1 = 95.1400 Indian rupees)

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Aug 5 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES LTD - USFDA CONDUCTED INSPECTION OF CO'S MANUFACTURING FACILITY AT HYDERABAD

• COHANCE LIFESCIENCES - RECEIVED A FORM FDA 483 CONTAINING FIVE OBSERVATIONS FOR HYDERABAD FACILITY

Source text: [ID:]

Further company coverage: COHA.NS

(([email protected];;))

Cohance Lifesciences' promoters, Jusmiral Holdings and Berhyanda Limited, have pledged 208 million shares (54.36% of total equity) to secure a USD 285 million term loan from a consortium of five international banks including Barclays, Deutsche Bank, and BNP Paribas. The loan, drawn under a facility agreement dated June 11, 2026, will refinance existing debt under a previous notes purchase agreement that was repaid and released on June 16. The pledge covers 80.4 million shares from Jusmiral Holdings (21.02% of the company) and 127.5 million shares from Berhyanda Limited (33.34%), with additional covenants restricting disposal of the remaining promoter holdings.

Powered by Tijori

** Shares of India's Cohance Lifesciences COHA.NS fall as much as ~8.6% to 443 rupees

** The pharmaceutical company's quarterly profit down ~83.8% y/y to 195.5 million rupees ($2.04 million), pressured by lower sales, higher costs

** Revenue from operations down ~26.3% y/y

** Jefferies downgrades COHA rating to "underperform" from "hold", cuts PT by 40 rupees to 300 rupees

** Trims FY27-FY28 EPS estimates by 14%-17%, citing near-term growth challenges and margin pressure from higher costs

** YTD, COHA stock down ~13%

($1 = 95.6300 Indian rupees)

(Reporting by Bipasha Dey in Bengaluru)

(([email protected];))

May 12 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES LTD MARCH-QUARTER CONSOL NET PROFIT 195.5 MILLION RUPEES

• COHANCE LIFESCIENCES LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 6.19 BILLION RUPEES

Source text: [ID:]

Further company coverage: COHA.NS

(([email protected];))

April 27 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES LTD - VIVEK SHARMA RESIGNS AS EXECUTIVE CHAIRMAN

• COHANCE LIFESCIENCES LTD - UMANG VOHRA DESIGNATED AS CHAIRMAN

• COHANCE LIFESCIENCES LTD - UMANG VOHRA DESIGNATED AS GROUP CEO EFFECTIVE MAY 20, 2026

Source text: ID:nnAZN4SSSIC

Further company coverage: COHA.NS

(([email protected];))

Feb 23 (Reuters) -

• JASTI FAMILY TRUST SELLS 7.7 MILLION SHARES OF COHANCE LIFESCIENCES IN BULK DEAL; JASUB PROPERTY BUYS STAKE- NSE DATA

Further company coverage: COHA.NS

(([email protected];;))

Feb 6 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES LTD - USFDA ISSUES WARNING LETTER TO COHANCE FACILITY

Source text: ID:nBSE8D0YGd

Further company coverage: COHA.NS

(([email protected];))

** Shares of Cohance Lifesciences COHA.NS slump 9.3% to 625.7 rupees, lowest since June 6, 2024

** Stock logs biggest intraday percentage loss since June 24, 2020

** Pharma co posts 46.5% y/y decline in September-quarter consol net profit; rev from ops drops about 8% y/y

** More than 1.4 mln shares change hands, 4.5x of 30-day avg

** COHA rated "strong buy" by 8 analysts on average; median target price is 1,190 rupees – data compiled by LSEG

** Stock down 45% YTD

(Reporting by Rudra Pratap Singh in Bengaluru)

(([email protected]))

** Shares of Cohance Lifescieces COHA.NS fall 4.8% to 919.60 rupees

** About 34.2 mln shares traded in a block deal, at a discount of 6.2% to last close, according to LSEG data

** Advent unit Jusmiral Holdings plans to offload up to 8.9% stake in Cohance Lifesciences via block deals worth about 30.7 billion rupees (~$350 mln), CNBC reports, which Reuters could not confirm

** Report adds shares being offered at floor price of 900 rupees apiece, 6.9% discount to last close

** COHA down 19.2% YTD

($1 = 87.9625 Indian rupees)

(Reporting by Urvi Dugar)

(([email protected]))

Sept 11 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES LTD - USFDA COMPLETES CGMP AUDIT AT ANDHRA PRADESH FACILITY

• COHANCE LIFESCIENCES LTD - INSPECTION CONCLUDED WITH ZERO FORM 483 OBSERVATIONS

Source text: ID:nBSEbgnF80

Further company coverage: COHA.NS

(([email protected];;))

** IIFL Capital initiates coverage on contract research and drug manufacturing firm Cohance Lifesciences COHA.NS with "buy" and PT of 1,140 rupees

** Brokerage says COHA's acquisitions of drugmakers NJ Bio and Sapala strengthen its position in the fast-growing market of antibody drug conjugates (ADC), also known as "guided missile drugs" as they directly target cancer cells, minimizing damage to healthy cells

** Jefferies' PT highest among six analysts tracking COHA - data compiled by LSEG

** Revenue contribution from COHA'S niche tech, which includes these new molecules, is expected to double from 17% in FY25 to over 35% by FY30 - Jefferies

** Avg rating of analysts on COHA at "strong buy"; median PT is 1,235 rupees - data compiled by LSEG

** YTD, COHA stock down 23.4%

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

** Shares of Cohance Lifesciences COHA.NS decline 6.8% to 918.7 rupees; on track for biggest intraday pct drop since August 2022

** Pharma co posts a 35% drop in first-quarter consol net profit; rev jumps ~13% but expenses are also up 22%

** About 327,000 shares traded, 1.7x the 30-day avg

** Year-to-date, stock down ~19%

** Despite Q1 results, stock rated "strong buy" on avg, median PT is 1,235 rupees

(Reporting by Manvi Pant in Bengaluru)

(([email protected]; +918447554364;))

Aug 13 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• COHANCE LIFESCIENCES JUNE-QUARTER NET PROFIT 525.7 MILLION RUPEES

• COHANCE LIFESCIENCES JUNE-QUARTER REVENUE FROM OPERATIONS 4.84 BILLION RUPEES

Source text: ID:nNSE8VynZb

Further company coverage: COHA.NS

(([email protected];))

June 20 (Reuters) - Cohance Lifesciences Ltd COHA.NS:

• TO SELL CR BIO UNIT FOR 160 MILLION RUPEES

• SALE EXPECTED TO COMPLETE IN Q2 FY2026

Source text: ID:nBSEbdc5cH

Further company coverage: COHA.NS

(([email protected];;))

April 25 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS - TO ISSUE 11 CO SHARES FOR EVERY 295 COHANCE LIFESCIENCES SHARES

Source text: ID:nNSEV6RDB

Further company coverage: SUVH.NS

(([email protected];))

** Suven Pharmaceuticals SUVH.NS rises 2.1% to 1,074 rupees after dropping 6.4% in the last two sessions amid a broader market drop triggered by Trump tariffs

** Day's rise comes after Goldman Sachs starts coverage with "buy", sets PT at 1,350 rupees - potential upside of 28.2% in the next 12 months

** Brokerage expects structural growth rebound for co starting this fiscal year, driven by sustained traction for its top five drugs, new drug approvals

** YTD, stock falls 7.5%

(Reporting by Bharath Rajeswaran in Bengaluru)

(([email protected]; +91 9769003463;))

Jan 1 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS LTD - CASPER PHARMA DISSOLVED AND AMALGAMATED WITH SUVEN PHARMACEUTICALS

Source text: ID:nBSE8lpNr3

Further company coverage: SUVH.NS

(([email protected];;))

Sept 19 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• VAIDHEESH ANNASWAMY DECIDED TO STEP DOWN AS EXECUTIVE CHAIRPERSON

• NAMES VIVEK SHARMA AS EXECUTIVE CHAIRMAN

Source text for Eikon: ID:nNSE3WRgk5

Further company coverage: SUVH.NS

(([email protected];;))

Aug 9 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• SUVEN PHARMACEUTICALS LTD JUNE-QUARTER CONSOL NET PROFIT 607.7 MILLION RUPEES

• SUVEN PHARMACEUTICALS LTD JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 2.31 BILLION RUPEES

Source text for Eikon: [ID:]

Further company coverage: SUVH.NS

(([email protected];))

** Shares of Suven Pharmaceuticals Ltd SUVH.NS up 4.9% at 700.50 rupees

** Contract drug manufacturer acquires smaller peer Sapala Organics for 2.3 billion rupees ($27.5 million) to bolster its contract and development manufacturing services (CDMO) business

** Earlier this year, SUVH merged with another CDMO firm, Cohance

** Sapala's "robust" margin profile and strong presence in Japan among key reasons for acquisition - SUVH presentation

** Over 305,000 shares traded, 1.6x 30-day avg volume

** Stock trims YTD losses to 4.3%, trails pharma stocks' .NIPHARM ~18% rise

($1 = 83.5300 Indian rupees)

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

June 13 (Reuters) - Suven Pharmaceuticals Ltd SUVH.NS:

• EXECUTED DEFINITIVE AGREEMENTS FOR ACQUIRING 100% OF SHARES IN SAPALA ORGANICS

• DEAL FOR 2.3 BILLION RUPEES

• CO AGREED TO INITIALLY ACQUIRE 67.5% BY WAY OF SECONDARY TRANSFER FROM SAPALA ORGANICS EXISTING SHAREHOLDERS

Source text for Eikon: ID:nBSE3qYcqh

Further company coverage: SUVH.NS

(([email protected];;))

** Shares of Suven Pharmaceuticals Ltd SUVH.NS fall as much as 4.8% to 602 rupees, their lowest since March 18

** Co reported a ~57% fall in its fourth-quarter consol net profit to 533.7 mln rupees ($6.4 mln), while rev fell 31.5% Y/Y

** "Revenue growth was impacted by shipment delays caused by client-specific inventory de-stocking," co said in a statement

** Stock on track to fall for the second straight day

** More than 581,000 shares traded as of 11:56 a.m. IST, 4.8x their 30-day moving avg

** SUVH last down 1.6%, adding to YTD losses of ~14.4%

($1 = 83.2875 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

** Shares of Suven Pharmaceuticals SUVH.NS up 12% in heavy volumes

** Stock eyes best day in more than 3 years

** Contract drug maker said it will merge with privately held Cohance Lifesciences in an all-stock deal to boost its contract and development manufacturing services (CDMO) business

** Trading volume tops 3 mln shares, more than 10x the 30-day moving avg

** Thursday's gains trim YTD losses to 2.5%; stock surged 46% in 2023

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

HYDERABAD, Feb 29 (Reuters) - Indian contract drug manufacturer Suven Pharmaceuticals SUVH.NS said on Thursday it will merge with Cohance Lifesciences in an all-share deal, as it looks to further scale up its contract and development manufacturing services (CDMO) business.

The company, however, did not mention the deal value.

Under the deal, all shareholders of privately held Cohance will be issued 11 shares of Suven for every 295 shares of Cohance based on the swap ratio, Suven said on Thursday.

Private equity firm Advent International wholly owns Cohance and has a significant stake in Suven Pharma, which was demerged from its parent entity Suven Life Sciences SUVP.NS in 2020.

The combined entity, which Advent has been looking to merge since 2022, will be 66.7% owned by Advent's entities and the remaining 33.3% will be held by public shareholders, the company said.

The merged platform will comprise three distinct business units - contract drug manufacturing of pharmaceuticals, specialty chemicals and active pharmaceutical ingredients (API), which are key elements added to drugs to produce desired health effects.

"Cohance's addition, particularly its fast-growing ADC (antibody-drug conjugates used in treating cancer) platform, reinforces our position as a leading CDMO platform," Suven said.

The addition of Cohance's API business will scale up Suven's formulation business, according to the company.

India's contract drug manufacturers are seeing a boost in their business as global pharmaceutical companies are looking for services outside of China in an attempt to diversify their supply chain.

"Proposed merger expected to be double-digit EPS accretive (without synergies) from first year of it being effective," Suven said.

The transaction is expected to conclude over the next 12-15 months subject to shareholder regulatory approvals, the company said.

($1 = 82.8699 Indian rupees)

(Reporting by Rishika Sadam; Editing by Shweta Agarwal)

(([email protected];))

** Shares of Suven Pharmaceuticals SUVH.NS up 1.4% at 673.85 rupees

** Co says two facilities have completed U.S. FDA inspections and no Form 483 was issued; form is issued when violations are observed, per FDA website

** Stock on track to end four-day losing streak if trend holds

** Stock surges as much as 5.2% to its highest level in a month

** Since slumping on Feb. 6 after Q3 profit drop, stock has regained 9.4%

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))